Kymera Historical Balance Sheet

KYMR Stock

USD 40.61 0.32 0.79%

Trend analysis of Kymera Therapeutics balance sheet accounts such as Total Current Liabilities of 73.3 M provides information on Kymera Therapeutics' total assets, liabilities, and equity, which is the actual value of Kymera Therapeutics to its prevalent stockholders. By breaking down trends over time using Kymera Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Kymera Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kymera Therapeutics is a good buy for the upcoming year.

Kymera Therapeutics Inventory

1.21

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

About Kymera Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Kymera Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Kymera Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kymera Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kymera currently owns. An asset can also be divided into two categories, current and non-current.

Kymera Therapeutics Balance Sheet Chart

At this time, Kymera Therapeutics' Non Currrent Assets Other are relatively stable compared to the past year. As of 01/18/2025, Other Assets is likely to grow to about 11 M, while Total Current Liabilities is likely to drop slightly above 73.3 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Total Stockholder Equity Net Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Kymera Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Kymera Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Kymera Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kymera Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Kymera Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.At this time, Kymera Therapeutics' Non Currrent Assets Other are relatively stable compared to the past year. As of 01/18/2025, Other Assets is likely to grow to about 11 M, while Total Current Liabilities is likely to drop slightly above 73.3 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	17.3M	84.7M	97.4M	102.2M
Total Assets	603.1M	575.8M	662.1M	446.0M

Short Long Term Debt Total Total Assets

Kymera Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.72	0.87	0.95	0.99	0.78	0.96	0.65	0.74	0.53	-0.88	0.88	0.65	0.78	-0.46	0.91	0.97	0.64	0.83	-0.15	0.72	0.92	0.93	0.77	0.99	0.73
Short Long Term Debt Total	0.72		0.94	0.69	0.66	0.51	0.82	1.0	0.35	0.45	-0.91	0.88	0.84	0.89	0.12	0.85	0.59	0.98	0.79	0.13	1.0	0.9	0.86	0.75	0.66	1.0
Other Current Liab	0.87	0.94		0.78	0.85	0.57	0.95	0.92	0.46	0.41	-0.98	0.89	0.81	0.84	-0.21	0.98	0.79	0.91	0.88	-0.08	0.94	0.99	0.97	0.71	0.85	0.95
Total Current Liabilities	0.95	0.69	0.78		0.91	0.91	0.89	0.62	0.87	0.66	-0.78	0.85	0.55	0.84	-0.3	0.8	0.94	0.59	0.71	0.01	0.69	0.84	0.84	0.88	0.91	0.68
Total Stockholder Equity	0.99	0.66	0.85	0.91		0.71	0.96	0.6	0.7	0.49	-0.87	0.84	0.6	0.71	-0.54	0.9	0.97	0.6	0.8	-0.29	0.66	0.91	0.93	0.66	1.0	0.68
Other Liab	0.78	0.51	0.57	0.91	0.71		0.7	0.43	0.96	0.63	-0.55	0.64	0.31	0.78	-0.19	0.57	0.82	0.39	0.47	0.19	0.51	0.63	0.63	0.87	0.71	0.49
Net Tangible Assets	0.96	0.82	0.95	0.89	0.96	0.7		0.77	0.66	0.52	-0.94	0.86	0.65	0.82	-0.39	0.97	0.93	0.77	0.82	-0.25	0.82	0.99	0.99	0.7	0.96	0.83
Property Plant And Equipment Net	0.65	1.0	0.92	0.62	0.6	0.43	0.77		0.26	0.42	-0.88	0.85	0.84	0.86	0.18	0.82	0.52	0.99	0.76	0.14	1.0	0.86	0.82	0.7	0.6	0.99
Current Deferred Revenue	0.74	0.35	0.46	0.87	0.7	0.96	0.66	0.26		0.68	-0.44	0.5	0.09	0.67	-0.3	0.49	0.82	0.24	0.31	-0.05	0.35	0.56	0.58	0.71	0.7	0.34
Net Debt	0.53	0.45	0.41	0.66	0.49	0.63	0.52	0.42	0.68		-0.39	0.51	0.14	0.73	0.24	0.32	0.49	0.45	0.11	-0.15	0.45	0.46	0.48	0.51	0.49	0.45
Retained Earnings	-0.88	-0.91	-0.98	-0.78	-0.87	-0.55	-0.94	-0.88	-0.44	-0.39		-0.91	-0.83	-0.81	0.25	-0.96	-0.79	-0.88	-0.89	0.08	-0.91	-0.97	-0.97	-0.69	-0.87	-0.92
Accounts Payable	0.88	0.88	0.89	0.85	0.84	0.64	0.86	0.85	0.5	0.51	-0.91		0.89	0.86	-0.08	0.85	0.76	0.83	0.87	0.13	0.88	0.89	0.87	0.84	0.84	0.88
Cash	0.65	0.84	0.81	0.55	0.6	0.31	0.65	0.84	0.09	0.14	-0.83	0.89		0.63	0.0	0.76	0.48	0.81	0.9	0.3	0.84	0.74	0.7	0.67	0.6	0.84
Non Current Assets Total	0.78	0.89	0.84	0.84	0.71	0.78	0.82	0.86	0.67	0.73	-0.81	0.86	0.63		0.16	0.74	0.7	0.85	0.6	0.13	0.89	0.84	0.83	0.84	0.71	0.88
Non Currrent Assets Other	-0.46	0.12	-0.21	-0.3	-0.54	-0.19	-0.39	0.18	-0.3	0.24	0.25	-0.08	0.0	0.16		-0.41	-0.58	0.2	-0.38	0.51	0.12	-0.3	-0.34	0.02	-0.54	0.1
Other Assets	0.91	0.85	0.98	0.8	0.9	0.57	0.97	0.82	0.49	0.32	-0.96	0.85	0.76	0.74	-0.41		0.85	0.81	0.91	-0.17	0.85	0.98	0.97	0.67	0.9	0.87
Cash And Short Term Investments	0.97	0.59	0.79	0.94	0.97	0.82	0.93	0.52	0.82	0.49	-0.79	0.76	0.48	0.7	-0.58	0.85		0.5	0.73	-0.23	0.59	0.86	0.88	0.71	0.97	0.6
Net Receivables	0.64	0.98	0.91	0.59	0.6	0.39	0.77	0.99	0.24	0.45	-0.88	0.83	0.81	0.85	0.2	0.81	0.5		0.72	0.06	0.98	0.86	0.83	0.63	0.6	0.99
Common Stock Shares Outstanding	0.83	0.79	0.88	0.71	0.8	0.47	0.82	0.76	0.31	0.11	-0.89	0.87	0.9	0.6	-0.38	0.91	0.73	0.72		0.1	0.79	0.86	0.83	0.71	0.8	0.79
Non Current Liabilities Total	-0.15	0.13	-0.08	0.01	-0.29	0.19	-0.25	0.14	-0.05	-0.15	0.08	0.13	0.3	0.13	0.51	-0.17	-0.23	0.06	0.1		0.13	-0.16	-0.24	0.46	-0.29	0.09
Capital Lease Obligations	0.72	1.0	0.94	0.69	0.66	0.51	0.82	1.0	0.35	0.45	-0.91	0.88	0.84	0.89	0.12	0.85	0.59	0.98	0.79	0.13		0.9	0.86	0.75	0.66	1.0
Other Current Assets	0.92	0.9	0.99	0.84	0.91	0.63	0.99	0.86	0.56	0.46	-0.97	0.89	0.74	0.84	-0.3	0.98	0.86	0.86	0.86	-0.16	0.9		0.99	0.72	0.91	0.91
Other Stockholder Equity	0.93	0.86	0.97	0.84	0.93	0.63	0.99	0.82	0.58	0.48	-0.97	0.87	0.7	0.83	-0.34	0.97	0.88	0.83	0.83	-0.24	0.86	0.99		0.67	0.93	0.88
Total Liab	0.77	0.75	0.71	0.88	0.66	0.87	0.7	0.7	0.71	0.51	-0.69	0.84	0.67	0.84	0.02	0.67	0.71	0.63	0.71	0.46	0.75	0.72	0.67		0.66	0.72
Net Invested Capital	0.99	0.66	0.85	0.91	1.0	0.71	0.96	0.6	0.7	0.49	-0.87	0.84	0.6	0.71	-0.54	0.9	0.97	0.6	0.8	-0.29	0.66	0.91	0.93	0.66		0.68
Property Plant And Equipment Gross	0.73	1.0	0.95	0.68	0.68	0.49	0.83	0.99	0.34	0.45	-0.92	0.88	0.84	0.88	0.1	0.87	0.6	0.99	0.79	0.09	1.0	0.91	0.88	0.72	0.68

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	487.2M	605.9M	603.1M	575.8M	662.1M	446.0M
Short Long Term Debt Total	18.0M	18.0M	17.3M	84.7M	97.4M	102.2M
Other Current Liab	7.2M	19.6M	23.9M	34.4M	39.5M	41.5M
Total Current Liabilities	110.6M	101.0M	63.3M	85.7M	98.5M	73.3M
Total Stockholder Equity	283.9M	459.6M	490.2M	395.0M	454.2M	278.6M
Other Liab	29.6M	77.9M	39.4M	28.2M	32.5M	38.6M
Net Tangible Assets	(74.4M)	283.9M	459.6M	490.2M	563.7M	591.9M
Property Plant And Equipment Net	10.8M	11.9M	13.3M	101.1M	116.2M	122.1M
Current Deferred Revenue	170.4M	101.0M	63.3M	37.9M	43.6M	73.0M
Net Debt	(13.0M)	(30.0M)	(51.1M)	(25.3M)	(29.1M)	(30.5M)
Retained Earnings	(128.8M)	(229.0M)	(383.8M)	(530.8M)	(477.7M)	(453.8M)
Accounts Payable	4.4M	4.0M	4.3M	7.1M	8.1M	4.6M
Cash	31.0M	48.0M	68.4M	110.0M	126.5M	68.7M
Non Current Assets Total	184.8M	38.3M	43.6M	170.4M	196.0M	205.8M
Non Currrent Assets Other	11.5M	(98.8M)	(122.0M)	7.9M	7.1M	7.5M
Other Assets	1.8M	1.6M	8.1M	9.1M	10.5M	11.0M
Cash And Short Term Investments	458.7M	567.6M	559.5M	374.9M	431.1M	383.9M
Net Receivables	1.4M	135K	2.5M	18.8M	21.6M	22.7M
Common Stock Shares Outstanding	17.3M	48.0M	53.9M	58.4M	67.1M	44.4M
Short Term Investments	265.2M	394.4M	338.8M	264.9M	304.7M	234.5M
Liabilities And Stockholders Equity	487.2M	605.9M	603.1M	575.8M	662.1M	446.0M
Non Current Liabilities Total	92.7M	45.2M	49.7M	95.1M	85.6M	68.4M
Capital Lease Obligations	18.0M	18.0M	17.3M	84.7M	97.4M	102.2M
Other Current Assets	4.7M	8.7M	9.7M	11.7M	13.4M	14.1M
Other Stockholder Equity	412.8M	689.3M	878.9M	926.3M	1.1B	1.1B
Total Liab	203.3M	146.3M	113.0M	180.8M	207.9M	167.4M
Net Invested Capital	283.9M	459.6M	490.2M	395.0M	454.2M	278.6M
Property Plant And Equipment Gross	20.7M	25.2M	29.1M	111.5M	128.2M	134.7M
Total Current Assets	302.3M	567.6M	559.5M	405.3M	466.1M	361.1M
Accumulated Other Comprehensive Income	(128K)	(660K)	(4.9M)	(552K)	(496.8K)	(521.6K)
Net Working Capital	191.7M	358.7M	348.1M	319.6M	367.6M	240.8M
Short Term Debt	6.5M	7.2M	7.9M	6.3M	7.3M	5.8M
Property Plant Equipment	22.1M	20.7M	11.9M	13.3M	15.3M	15.4M

Pair Trading with Kymera Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kymera Stock

0.61

23Andme Holding

Pair Corr

Moving against Kymera Stock

0.73	DRTS	Alpha Tau Medical	Pair Corr
0.73	CDIOW	Cardio Diagnostics	Pair Corr
0.58	DMAC	DiaMedica Therapeutics	Pair Corr
0.52	VCEL	Vericel Corp Ord	Pair Corr
0.52	SABSW	SAB Biotherapeutics	Pair Corr

The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.

The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kymera Historical Balance Sheet

Kymera Therapeutics Inventory

1.21

About Kymera Balance Sheet Analysis

Kymera Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Net Debt

Kymera Therapeutics balance sheet Correlations

Kymera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kymera Therapeutics balance sheet Accounts

Pair Trading with Kymera Therapeutics

Moving together with Kymera Stock

Moving against Kymera Stock

Additional Tools for Kymera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Capital Lease Obligations

Retained Earnings	- 0.98	Other Current Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings
Other Assets	- 0.96	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Property Plant And Equipment Gross	- 0.92	Retained Earnings